Tonix Pharmaceuticals (NASDAQ: TNXP) insider transactions
In the twelve months to 10 November 2026, executives and directors of Tonix Pharmaceuticals reported 0 open-market sales and 7 open-market purchases of 34,415 shares ($458,758), by 4 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 27 August 2026 | Lederman Seth | Chief Executive Officer | Open-market purchase | +2,000 | $13.79 | 11,005 | Form 4 |
| 20 August 2026 | Bagger Richard H | Director | Open-market purchase | +1,000 | $12.60 | 1,000 | Form 4 |
| 30 June 2026 | Saenger Bradley | Chief Financial Officer | Other | +1,453 | $10.91 | 2,154 | Form 4 |
| 12 June 2026 | Taylor Carolyn E. | Director | Open-market purchase | +1,415 | $10.55 | 1,833 | Form 4 |
| 9 June 2026 | Lederman Seth | Chief Executive Officer | Open-market purchase | +5,000 | $11.79 | 9,005 | Form 4 |
| 8 June 2026 | Stillwell Richard Newcomb | Director | Open-market purchase | +5,000 | $11.65 | 5,000 | Form 4 |
| 31 March 2026 | Lederman Seth | Chief Executive Officer | Open-market purchase | +5,000 | $12.62 | 20,001 | Form 4 |
| 18 March 2026 | Lederman Seth | Chief Executive Officer | Open-market purchase | +15,000 | $14.89 | 15,001 | Form 4 |
| 21 August 2025 | Taylor Carolyn E. | Director | Open-market purchase | +418 | $36.03 | 418 | Form 4 |
| 20 August 2025 | Treco James | Director | Open-market purchase | +250 | $36.00 | 250 | Form 4 |
| 15 May 2025 | Lederman Seth | Chief Executive Officer | Open-market purchase | +4,000 | $21.55 | 4,005 | Form 4 |
| 5 February 2025 | Bagger Richard H | Director | Other | −0 | $0.20 | 0 | Form 4 |
| 5 February 2025 | Treco James | Director | Other | −0 | $0.30 | 0 | Form 4 |
| 5 February 2025 | Bell Margaret Smith | Director | Other | −1 | $0.15 | 0 | Form 4 |
| 5 February 2025 | Morris Jessica Edgar | Chief Operating Officer | Other | −1 | — | 0 | Form 4 |
| 5 February 2025 | Lederman Seth | Chief Executive Officer | Other | −5 | $3.38 | 5 | Form 4 |
| 5 February 2025 | Lederman Seth | Chief Executive Officer | Other | −0 | $3.30 | 1 | Form 4 |
| 5 February 2025 | Lederman Seth | Chief Executive Officer | Other | −1 | $0.15 | 0 | Form 4 |
| 5 February 2025 | Sullivan Gregory M | Chief Medical Officer | Other | −0 | $1.47 | 0 | Form 4 |
| 5 February 2025 | Saenger Bradley | Chief Financial Officer | Other | −0 | — | 0 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Tonix Pharmaceuticals page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.